Contact Us

Cell & Gene Product Launch Services

Cell & Gene Commercialization

Simplifying the path to launch for highly sophisticated therapies

JOIN US FOR A PANEL DISCUSSION AT MEETING ON THE MESA ON OCTOBER 9

Anatomy of a CGT Launch: Operationalizing Cell and Gene Therapy

Our panel, lead by Kyle Felmet, VP, Commercialization will delve into the unique market access, logistical, regulatory, and strategic challenges of launching CGT therapies, from ensuring seamless distribution and patient-specific logistics to navigating complex reimbursement landscapes and coordinating cross-functional teams. Gain insights from industry leaders who have successfully brought cell and gene therapies to market, sharing their experiences and best practices. Discover innovative solutions and actionable strategies to overcome the hurdles in bringing groundbreaking therapies to patients.

LEARN MORE
Kyle Felmet

About
Cell & Gene Therapy Launch

The landscape of cell & gene therapies continues to evolve at breakneck speed.

With hundreds of companies developing new therapies, the market is expected to grow at a rate of 18% over the next decade. So the stakes are higher than ever for CGT companies, even as bringing CGTs to the market is as costly and complicated as ever.

At Two Labs, we provide CGT companies with tested, proven-by-results strategy and implementation that eliminates the variables in launching and managing CGTs. With our team’s combined 100+ years of industry experience and established track record of over 280 consulting engagements – including supporting the development and launch of over 20 cell & gene drugs – we provide a wide range of services that positions CGT innovators for market success.

Featured Services

Product Launch

Having supported over 280 launches, our team has the expertise and experience needed to manage the complex commercialization process from where you are to where you want to go, avoiding costly and time-consuming missteps while supporting the market success of your product.
Learn More

Compliance

We have helped bring over 280 biopharma products to market, so we know how to support your team and optimize your state licensing, drug price transparency, compendia data, and EHR visibility in order to differentiate your product to physicians, payers, patients, and other stakeholders.
Learn More

Medical Affairs & Communications

Two Labs’ Medical Affairs & Communications provides vital support in finding the correct audience for your product’s scientific data and strategic goals to tailor a medical communications plan to your needs.
Learn More

Specialty Channel Strategy and Implementation

With specialty products, we help you make the right decisions around your channel strategy, including selecting the right 3PL partner, speciality distributors, and specialty pharmacy partners.
Learn More

Patient Services and Implementation

We provide a comprehensive scope of patient support services to help you design and implement a best-in-class patient program and execute a post-launch assessment to ensure customer satisfaction and program optimization.
Learn More

Meet Your Team of Experts

Our experts are the reason 90% of our clients would recommend Two Labs to a colleague.

Courtney Johnson

Courtney Johnson

Vice President, Commercialization

View Bio

Kyle Felmet

Kyle Felmet

Vice President, Commercialization

View Bio

What can we help you with today?

No matter where you are in the process, we’re here to support, advise, and implement key strategies to ensure the success of your product.

Additional Cell & Gene Insights

Cell & Gene Therapies: How the Industry is Innovating & What Emerging Manufacturers Need to Know

Cell and gene therapies are reshaping the industry landscape. In this ebook, Two Labs’ Vice President of Specialty Commercialization, Kyle Felmet, shares much-needed guidance on the effects of the rising number of FDA-approved CGTs, discussing what that growth means for payers and the policy changes that will accompany it.

Learn More
Adding State Licensing to Your Cell and Gene Launch Strategy

Adding State Licensing to Your Cell and Gene Launch Strategy

July 16, 2021
The main question that sits at the center of the most common licensing questions and obstacles for cell and gene strategies: how do companies license a product that is often never touched by the parties that need to hold the license?
Read More >